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Abstract
Background: Recommended therapy duration for patients hospitalized with cellulitis is 10–14 days. Unnecessary
use of antibiotics is one of the key factors driving resistance. Recent studies have shown that antibiotic therapy for
cellulitis in outpatients can safely be shortened, despite residual inflammation. This study will compare in hospitalized
patients the safety and effectiveness of shortening antibiotic therapy for cellulitis from 12 to 6 days.
Methods/design: In a multicenter, randomized, double-blind, non-inferiority trial, adult patients admitted with cellulitis
will be included. Cellulitis is defined as warmth, erythema, and induration of the skin and/or subcutaneous tissue, with
or without pain (including erysipelas). All patients will initially be treated with intravenous flucloxacillin, and will be
evaluated after 5–6 days. Those who have improved substantially (defined as being afebrile, and having a lower cellulitis
severity score) will be randomized at day 6 between additional 6 days of oral flucloxacillin (n = 198) or placebo (n = 198).
Treatment success is defined as resolution of cellulitis on day 14 (disappearance of warmth and tenderness,
improvement of erythema and edema), without the need of additional antibiotics for cellulitis by day 28. Secondary
endpoints are relapse rate (up to day 90), speed of recovery (using a cellulitis severity score until day 28, and VAS scores
on pain and swelling until day 90), quality of life (using the SF-36 and EQ-5D questionnaires) and costs (associated with
total antibiotic use and health-care resource utilization up to day 90).
Discussion: Inclusion is planned to start in Q2 2014.
Trial registration: ClinicalTrials.gov (NCT02032654) and the Netherlands Trial Register (NTR4360).
Keywords: Cellulitis, Erysipelas, Skin infections, Antibiotics, Flucloxacillin, Therapy duration, Hospital setting,
Randomised controlled trial
Background
Cellulitis is an acute, spreading pyogenic inflammation
of the skin (dermis) and subcutaneous tissue, usually
complicating a wound, ulcer or dermatosis [1]. Erysip-
elas, while originally considered a separate disease entity
with a well-defined raised edge and more prominent
systemic symptoms, is now considered one of the mani-
festations of cellulitis, owing to physicians often not be-
ing able to make the clinical distinction, and the similar
spectrum of causative agents [2-4]. Cellulitis is among
the most frequent infections leading to hospitalization
[5]. In the USA, hospital visits for cellulitis and abscesses
increased from 17.3 to 32.5 per 1000 person-years be-
tween 1997–2010, resulting in 600.000 hospitalizations
in 2010 [6]. Similarly, the combined incidence of cellu-
litis and erysipelas of the leg (CEL) in the Netherlands
increased from 1.7 to 22 per 1000 persons-years between
2001–2007, of which 5-10% were hospitalized. This in-
crease is probably due to a rise in both the elderly
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population, and the number of patients with diabetes or
other causes of immune suppression [7,8]. Relapse rates
are around 12% after 21 days to a year [9-11], and up to
14-29% after three years [11-13].
As of yet, there is no consensus on admission criteria
or rating scales of severity [14,15]. Patients admitted to
the hospital for cellulitis generally receive their initial
antibiotic regimen intravenously (IV). After initial IV
therapy, switching to oral antibiotics is generally ac-
cepted when patients are afebrile, inflammatory symp-
toms are regressing and inflammatory markers are
improving [16,17]. As most cellulitis cases are caused by
streptococci and Staphylococcus aureus, Dutch national
guidelines advise 10–14 days of flucloxacillin for patients
with cellulitis (dosage: oral 500 mg q.d.s. or IV 1000 mg
q.d.s.) [18]. This takes into account that methicillin-
resistant Staphylococcus aureus (MRSA) prevalence in
the Netherlands is still well below 5%, while it is an in-
creasing problem in many parts of the world [19]. The
Infectious Diseases Society of America (IDSA) recom-
mends a beta-lactam for non-purulent cellulitis, MRSA
targeting antibiotics for purulent cellulitis, and treatment
durations between 5–10 days for outpatients and 7–14
days for inpatients [20]. However, due to a lack of evi-
dence the recommended duration of therapy in both of
these guidelines is mainly based on expert opinion [2].
It is postulated that, like persisting radiological abnor-
malities in pneumonia [21], erythema that persists after
a few days of antibiotic treatment is due to residual in-
flammation. If this is indeed the case, this would allow
physicians to discharge patients or end antibiotic treat-
ment before full symptom resolution [22,23]. A recent
study reported that 5 days of antibiotics is not inferior to
10 days of antibiotics in outpatients with uncomplicated
cellulitis responding to initial therapy, despite residual
symptoms on day 5 [23]. In line, studies on urinary tract
infections, respiratory tract infections, and other infec-
tious diseases have also demonstrated that antibiotic
therapy can safely significantly be shortened [24-31]. In
light of these studies, we hypothesize that for patients
hospitalized with cellulitis, treatment with a short course
(6 days) of antibiotics is not inferior to a standard course
(12 days), if they respond to initial treatment.
Methods/design
The study is registered in the Netherlands Trial Register
(NTR4360) and on ClinicalTrials.gov (NCT02032654).
The publication on main study results will be in accord-
ance with the Consolidated Standards of Reporting Trials
(CONSORT) statement [32].
Design and sites
The DANCE trial is an investigator-initiated, prospect-
ive, multicenter, randomized, investigator-, caregiver-
and patient blinded non-inferiority trial, with two paral-
lel groups with an allocation ratio of 1:1. Subjects will
initially be enrolled at eight Dutch hospitals: i) Academic
Medical Center, Amsterdam; ii) VU University Medical
Center, Amsterdam; iii) University Medical Center, Utrecht;
iv) Diakonessenhuis, Utrecht; v) Flevoziekenhuis, Almere;
vi) Onze Lieve Vrouwe Gasthuis, Amsterdam; vii) Sint
Lucas Andreas Hospital, Amsterdam; viii) Slotervaart
Hospital, Amsterdam. These sites serve a large, densely
populated urban area of the Netherlands. In the case of
slow enrolment, additional hospitals will be approached
to participate in the study. This study will be conducted
in accordance with the Declaration of Helsinki and was ap-
proved by the medical ethics committee of the Academic
Medical Center, Amsterdam. The Boards of Directors of all
participating sites subsequently approved the execution of
the study in their centers.
Participants
Adult patients meeting the in- but not exclusion criteria
are eligible (see below). Cellulitis is defined as warmth,
erythema, and induration of the skin and/or subcutane-
ous tissue, with or without pain (including erysipelas)
[33]. Eligible patients are approached by local investiga-
tors who will provide them with the patient information
folder. Two investigators (DRC and a research nurse)
will be responsible for the informed consent process and
data collection in every site. They will perform all study
procedures. If this proves to be excessively time consum-
ing, additional investigators will be recruited and trained.
After providing consent, subjects can leave the study at
any time for any reason if they wish to do so, without
any consequences. The investigator can decide to with-
draw a subject from the study for urgent medical reasons.
Once randomized, withdrawn subjects will not be re-
placed, in accordance with the intention-to-treat principle.
The inclusion criteria are:
 Admitted to receive intravenous antibiotics for
cellulitis/erysipelas
 18 years of age or older
 Capable of giving written informed consent, able to
comply with study requirements and restrictions
The exclusion criteria are:
 Allergy for flucloxacillin, other beta-lactam
antibiotics or one of the additives, or history of
flucloxacillin-induced hepatitis or liver enzyme
disorders.
 Concurrent use of antibiotics for other indications
 Alternative diagnosis accounting for the clinical
presentation.
 All cases involving any of the following factors:
o Use of antibiotics with Gram-positive activity
for more than 4 days in the past 7 days
Cranendonk et al. BMC Infectious Diseases 2014, 14:235 Page 2 of 7
http://www.biomedcentral.com/1471-2334/14/235
o Intensive care unit admission during the last
7 days
o Severe peripheral arterial disease (Fontaine IV)
o Severe cellulitis necessitating surgical
debridement or fascial biopsy
o Necrotizing fasciitis
o Periorbital or perirectal involvement
o Surgery
o Life expectancy less than one month
o Risk factors associated with Gram-negative
pathogens as a causative agent [34]:
▪ Chronic or macerated infra-malleolar ulcers, or
infra-malleolar ulcers with previous antibiotic
treatment, in patients with diabetes mellitus [35].
▪ Neutropenia
▪ Cirrhosis (Child-Pugh class B or C)
▪ Intravenous drug use
Procedures
All participants will receive regular antibiotics (flucloxacil-
lin, or another empiric beta-lactam with activity against
S. aureus that is shortly after replaced by flucloxacillin)
for the first 6 days of treatment. Treatment will be
started intravenously, but a switch to oral medication
can be performed at the caregiver’s discretion when the
patient has become afebrile and the cellulitis shows im-
provement. Participants will be assessed by one of the
investigators at multiple time points (Table 1).
Participants responding to initial therapy, defined as
absence of fever (temperature > 38.0°C) and improve-
ment in cellulitis severity score by day 5–6 compared to
the first 24 hours of admission, and able to take oral
medication will be randomized into one of two groups.
One group will receive 6 more days of flucloxacillin
(500 mg q.d.s.), while the other group will receive 6 days
of placebo (500 mg q.d.s.). Of note, patients with a cre-
atinine clearance of <10 ml/min or those on haemodialy-
sis will receive 500 mg of trial medication t.d.s. Patients
are not randomized if: i) they require ICU admission,
concomitant antibiotics, or surgical intervention, or de-
velop an allergic reaction (see exclusion criteria); ii) their
blood cultures become positive (excluding contamin-
ation); or iii) they do not improve. Other aspects of
treatment are according to standard of care. Compression
therapy should be encouraged, but is not mandatory, and
is at the discretion of the caregiver. Patients will be in-
formed about the correct use of the trial medication. To
register adherence, patients will be asked to bring left-over
trial medication to their day 14 visit, at which the capsules
will be counted and afterwards destroyed.
Assessments
Standard demographic and other patient characteristics will
be collected, including age, gender, non-trial medication
use, comorbidity, ethnic background, recreational drug use,
smoking, body weight, residential status, and risk factors
for cellulitis [6] (i.e. venous insufficiency, lymphoedema,
peripheral arterial disease, immunosuppression, diabetes,
trauma, tattoos, ulcers, eczema, tinea pedis and burns). The
extent of cellulitis (length and width, lesion surface area)
and presence of lymphadenopathy will be recorded on pre-
determined time points (Table 1). A cellulitis severity score
will be used, which measures erythema, warmth, tender-
ness, edema, ulceration, drainage and fluctuation. Each par-
ameter is scored with a numerical value of 0–3 (none, mild,
moderate, and severe, respectively). This has been used pre-
viously in a trial on duration of therapy for uncomplicated
cellulitis [23].
The two investigators responsible for data collection
will standardize these assessments by performing simul-
taneous assessment at the beginning of the study. When
five patients have been scored independently with identi-
cal scores, the investigators will start assessing patients
Table 1 Study assessments, questionnaires and specimen
collections




















Physical examination X X X X
Cellulitis severity
score
X X X X X
VAS X X X X X X
Medication adherence X





SF-36 X X X
EQ-5D X X X
HCRUQ X X X
Specimen collection
Blood samples X X X X X
Skin biopsy* X
Skin swabs X X
VAS = visual analog scales on pain and swelling; SF-36 = Short Form (36)
questionnaire; EQ-5D = EuroQol-5D questionnaire; HCRUQ = health-care
resource utilisation questionnaire. *only performed in patients admitted to the
main study site.
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on their own. After 100 patients have been assessed, the
investigators will again assess five patients together. VAS
scores and questionnaires will be collected through a
web survey tool. Microbiological culture results and
hematology and chemistry lab results will be collected
from regular care, when available. Additionally, blood
samples will be taken at multiple time points, and skin
biopsies and swabs will be taken from selected patients
on admission.
Outcome measures
The primary outcome is resolution of cellulitis at day 14,
defined as disappearance of warmth and tenderness at
the site of infection, with substantial improvement in
erythema and edema, and without recurrence by day 28,
defined as the need for additional antibiotic therapy for
cellulitis.
Secondary outcomes are recurrence of cellulitis by
day 90; speed of recovery, determined by improvement
in cellulitis severity score and through self-assessment
of subjective pain and swelling on visual analog scales
(VAS) from 0–10; mean health-related quality of life,
using the SF-36 and EQ-5D questionnaires; and costs,
associated with total antibiotic use and other health-
care resource utilisation, measured with modified ver-
sions of iMTA’s Productivity Cost Questionnaire (iPCQ)
and Medical Consumption Questionnaire (iMCQ).
Blood samples and skin biopsies will be used for bio-
marker discovery, fundamental research, and skin micro-
biota analyses.
Randomization and blinding
Patients eligible for randomization will be allocated to ei-
ther (1) flucloxacillin or (2) placebo in a 1:1 randomization
ratio, using the online ALEA® software developed by the
NKI-AVL (Amsterdam, NL). This independent central
randomization service will create a computer generated
random schedule of blocks with random block sizes
(maximum block size of 6), stratified for presence of
diabetes mellitus and study site. Upon randomization,
the software will generate a randomization number for
the investigators, and will send an automated e-mail to
the appropriate pharmacy with the randomization
number and randomization result. Pharmacies will dis-
pense randomly numbered trial medication containers
to the patients, depending on the randomization result,
working from a confidential list which describes the
content (flucloxacillin or placebo) of each numbered
container. Flucloxacillin and placebo are in similar cap-
sules, and are administered in the same dosage and
duration, leading to blinding of patients, investigators
and caregivers. The randomization code will only be
broken in case the Data Safety Monitoring Board
(DSMB) advises to do so.
Sample size
When the sample size in each group is 198 (396 total), a
two-group large-sample normal approximation test with
a one-sided 0.050 significance level will have 80% power
to reject the null-hypothesis that 6 days of antibiotics is
not inferior to 12 days of antibiotics. This assumes a
conservatively estimated treatment failure rate of 20%,
and considers a 10% absolute difference in treatment
failure rate between the two groups as equivalence limit.
Analysis plan
Statistical analysis will be performed using the modified
intention-to-treat principle (mITT), including all ran-
domized patients who received at least one dose of the
study medication. Missing data will be handled with
multiple imputation. Baseline assessments and outcome
parameters will be summarized. Continuous variables
will be summarized with standard descriptive statistics,
categorical variables with frequencies and percentages.
For the primary outcome, the proportion of successful
treatments will be calculated for the two groups, and the
absolute risk difference (with one sided 95% confidence
limit) will be estimated to evaluate the non-inferiority
hypothesis (Table 2). In a secondary analysis, the differ-
ence in proportion in the two groups will be adjusted for
relevant baseline covariates, using a logistic regression
analysis. The difference in proportion of successful treat-
ments will be estimated at mean values for the covari-
ates. Differences in secondary outcome parameters will
be reported as relative risk or mean difference (with 95%
confidence interval), and p-values for statistical signifi-
cance estimated with the Chi-square test, t-test or Mann–
Whitney test, where appropriate. A Kaplan-Meier analysis
will be performed to compare the time to relapse (defined
as requiring additional antibiotics for cellulitis) between
the two groups.
A per protocol analysis will also be performed, for this
analysis the following randomized patients of whom the
compliance is clear will be included: patients with treat-
ment failure who have received at least 24 hours of study
medication, and patients with treatment success who
have received at least four days of study medication.
For this analysis treatment success is defined as reso-
lution of cellulitis at 14 days – disappearance of warmth
and tenderness at the site of infection, with substantial
improvement in erythema and edema –without recur-
rence by day 28, defined as the need of additional anti-
biotic therapy for cellulitis [23]. Treatment failure is
defined as the persistence or progression of signs and
symptoms of the acute process at 14 days after
randomization, a recurrence before day 28, or the inabil-
ity to complete the study owing to adverse events. The
response is deemed indeterminate when the patient (i)
received less than 80% of the study drug for reasons
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other than treatment failure, (ii) acquired a concomitant
infection outside of the skin requiring antibiotic treat-
ment, (iii) was lost to follow-up, or (iv) died unrelated to
the primary diagnosis.
Two subgroup analyses are planned, and statistically
tested with interaction effects: one for patients with dia-
betes mellitus, and one based on the cellulitis severity
score. Diabetes mellitus is known to influence outcome
in patients treated for complicated skin and skin struc-
ture infections, through multiple suggested mechanisms
[36]. A high cellulitis severity score reflects an extensive
local inflammatory response, which might indicate a
higher grade of infection that possibly requires more in-
tensive or prolonged antibiotic therapy.
Data safety monitoring board
An independent DSMB has been established, consisting
of two infectious disease specialists and a methodologist.
They will evaluate mortality after 198 patients have com-
pleted the trial. Given the expected low mortality rates
[37], the power to detect differences in mortality at this
stage will be very low. Therefore, the DSMB will qualita-
tively evaluate all deaths for their possible relation with
the given treatment. Only in case of striking differences
between the two arms the DSMB will inform investigators
and the medical ethics committee. The frequency of other
DSMB meetings will depend on the study proceedings
and the judgment of the DSMB chair.
Discussion
It is important that antibiotic exposure is kept to a mini-
mum without compromising patient safety, in order to
minimize the emergence of antibiotic resistance [38].
Unnecessary usage of antibiotics, like prolonged treat-
ment duration, is one of the key factors driving resist-
ance [39]. Ideally, the most narrow-spectrum antibiotic
is used for the shortest period of time. The problem is
that antibiotic treatment duration studies, especially for
cellulitis, are relatively scarce amidst the plethora of clin-
ical trials that usually compare newer to older antibi-
otics, sometimes with different durations. Only one trial
has been published that was specifically designed to exam-
ine treatment duration in patients with cellulitis; however
that one was performed in an outpatient setting [23]. This
study will be the first to investigate the optimal antibiotic
treatment duration for cellulitis in hospitalized patients, a
group of patients that has increased significantly over the
last few years and is responsible for the bulk of the cellu-
litis associated health care expenditure.
Table 2 Statistical analysis plan
Variable/outcome Hypothesis Outcome measure Methods of analysis
1. Primary
Resolution without relapse Intervention not inferior
to control
Percent cured on day 14 without relapse
by day 28 [binary]
Absolute risk difference
2. Secondary
Relapse by day 90 No difference Percent with relapse [binary] Chi2 ➔ Relative risk
Time to relapse No difference Relapse after cure [time to event] Kaplan-Meier survival analysis
Objective speed of recovery No difference Cellulitis severity score [continuous] Student’s T-test or Mann–Whitney U test
Subjective speed of recovery No difference Visual analogue scales of pain and swelling
[continuous]
Student’s T-test or Mann–Whitney U test
Quality of life No difference SF-36 questionnaire score at day 1, 28 and
90 [continuous]
Student’s T-test or Mann–Whitney U test
Additional antibiotic usage No difference Total amount of additional antibiotic use,
in DDD [continuous]
Student’s T-test or Mann–Whitney U test
Health care utilization No difference Total treatment associated costs, Health
Care Utilization Questionnaire [continuous]
Student’s T-test or Mann–Whitney U test
3. Subgroup analyses




Regression analysis, with interaction term
for severity score
Diabetes mellitus vs no
diabetes mellitus
Diabetes affects cure rate Regression analysis, with interaction term
for (no) diabetes
4. Sensitivity analyses Intervention not inferior
to control
All outcomes
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One of the current study protocol’s strong points is
that the in- and exclusion criteria allow for a large group
of cellulitis patients to be included, while still excluding
accepted confounders, making the results applicable to a
large population. Randomizing at day 5–6 allows for bet-
ter implementation of the results into clinical practice,
since response to initial therapy will be the main deter-
minant when deciding on cessation or continuation of
treatment. The short time period in which the primary
outcome is measured will hopefully lead to a minimal
loss to follow-up. Another strong point is data accuracy,
as we will limit the number of main investigators who
will assess the outcome parameters, in order to reduce
inter-observer variability. Photographs of selected pa-
tients will be used to check the accuracy of the mea-
sured cellulitis severity scores.
An important challenge will be patient recruitment, as
in many randomized controlled trials. We will evaluate
the recruitment rate at multiple time points, and if it is
too low, additional centers will be approached to assist
in inclusion. This should not interfere with data quality,
as the same investigators will continue to perform the
study procedures, despite the increasing number of par-
ticipating centers. Attention will also be given to compli-
ance, as trial medication is one capsule size larger than
regular flucloxacillin, possibly leading to decreased com-
pliance and thus bias towards non-inferiority. This will
be, at least partially, mitigated by careful explanation of
the necessity of taking trial medication upon entrance
into the trial, and performing pill-counts at the end of
the study.
If this trial shows non-inferiority of short course anti-
biotic therapy in cellulitis, this would allow for systemat-
ically shortening therapy for the entire spectrum of skin
and soft tissue diseases [23].
Trial status
Patient recruitment for the trial will start from the begin-
ning of 2014. Data collection is estimated to finish in 2017.
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